Stroke, Acute Clinical Trial
Official title:
A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke
The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.
Status | Completed |
Enrollment | 40 |
Est. completion date | June 2008 |
Est. primary completion date | May 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Acute ischemic stroke with onset within 12 hours before randomization with baseline NIHSS > 6 and < 22 Exclusion Criteria: General Exclusion Criteria - Participation in another study with an investigational drug or device within the previous 30 days, prior participation in the present study, or planned participation in another trial within the time frame of the current trial - Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for hemorrhage - Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy test Stroke Related Exclusion Criteria - Neurological deficit that has led to stupor or coma (National Institutes of Health Stroke Scale [NIHSS] Level Of Consciousness Item 1a score >or=2) - High clinical suspicion of septic embolus - Thrombosis involving cerebral veins - Rapidly improving neurological signs at any time before initiation of study drug administration Imaging Related Exclusion Criteria - Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the brain or gradient recalled echo (GRE) magnetic resonance imaging - CT or MRI evidence of nonvascular cause for the neurological symptoms - Large hypodensity on CT involving > 1/3 of the middle cerebral artery (MCA) territory - Baseline DWI volume > 1/3 of the MCA territory - Signs of mass effect causing shift of midline structures on CT or MRI - Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation, claustrophobia or known sensitivity to MRI contrast agents) Safety Related Exclusion Criteria - Congenital or acquired coagulopathy causing either of the following 1. activated partial thromboplastin time prolongation greater than 2 seconds above the upper limit of normal (ULN) for local laboratory 2. International normalized ratio (INR) of 1.4 or more. - Uncontrolled hypertension defined as a systolic blood pressure > 180 mm Hg or a diastolic blood pressure > 100 mm Hg on 3 separate occasions at least 10 minutes apart or requiring continuous intravenous (IV) therapy. - History of stroke within the previous 3 months - Seizures at any time between stroke onset to planned initiation of study drug - History of intracranial hemorrhage - History of surgery, lumbar puncture, biopsy or trauma to internal organs within the previous 30 days. - Major trauma at the time of stroke - Head trauma within the previous 90 days. - Known bleeding diathesis. - Baseline platelet count < 100 X 10^9/L. - Blood glucose > 400mg/dl or <50 mg/dl if administration of glucose does not rapidly reverse neurological deficit Exclusion Criteria That May Potentially Interfere with Outcome Assessment - Life expectancy <3 months - Other serious illness that in the opinion of the investigator may confound clinical assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer) Exclusion Criteria Related to Concomitant Medication - If treatment with tPA is indicated - Treatment with rtPA or any other thrombolytic agent for the qualifying stroke - Administration of intra-arterial or systemic thrombolytic therapy in previous 7 days - Need for antiplatelet agent, unfractionated or heparin-related products, direct thrombin inhibitor, oral anticoagulant within 24 hours after treatment bolus. - Treatment with low molecular weight heparin, direct thrombin inhibitor, or GPIIb/IIIa antagonists within 48 hours prior to randomisation - Treatment with vitamin-K antagonists or heparin (or heparin-related compounds) which results in either an INR>1.4 or an aPTT>2 times control (ULN for the hospital laboratory) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Universitatsklinik fur Neurologie | Graz | |
Austria | AKH Linz Neurolog Abt | Linz | |
Austria | Allgemeines Offentliches Krankenhaus der | Linz | |
Austria | Landesnervenklinik Wagner-Jauregg | Linz | |
Belgium | Cliniques Universitaires St Luc | Brussels | |
Belgium | Gasthuisburg Hospital | Leuven | |
Germany | Universitätsklinikum Erlangen | Erlangen | |
Germany | Universitatsklinikum Essen | Essen | |
Germany | Klinikum der J.W Goethe Univeristy | Frankfurt | |
Germany | Universitatsklinikum Freiburg | Freiburg | |
Germany | Georg August Universitat Gottingen | Gottingen | |
Germany | Universitatskrankenhaus Hamburg-Eppendorf | Hamburg | |
Germany | Universitatsklinikum Leipzig | Leipzig | |
Germany | Klinikum Minden, Chefarzt der Neurologischen Klinik | Minden | |
Germany | Klinikum rechts der Isar der TU München | München | |
Germany | HSK Dr. Horst Schmidt Hospital | Wiesbaden |
Lead Sponsor | Collaborator |
---|---|
ThromboGenics |
Austria, Belgium, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intracranial haemorrhage | 24 hours and Day-7 | Yes | |
Primary | Change from Baseline in NIHSS | Day7 and Day-90 | No | |
Secondary | Barthel Index and modified Rankin scale | Day-90 | No | |
Secondary | Markers of systemic lysis | Baseline, end of treatment, 6, 12, 24, 72 and 96 hours | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Completed |
NCT03574038 -
Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke
|
N/A | |
Completed |
NCT03679637 -
Tablet-based Aphasia Therapy in the Acute Phase After Stroke
|
N/A | |
Completed |
NCT03633422 -
Evaluation of Stroke Patient Screening
|
||
Completed |
NCT04088578 -
VNS-supplemented Motor Retraining After Stroke
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Not yet recruiting |
NCT05534360 -
Tenecteplase Treatment in Ischemic Stroke Registry
|
||
Withdrawn |
NCT05786170 -
ERILs Und SNILs Unter SOC
|
N/A | |
Not yet recruiting |
NCT04105322 -
Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients
|
N/A | |
Recruiting |
NCT03132558 -
Contrast Induced Acute Kidney in Patients With Acute Stroke
|
N/A | |
Completed |
NCT02893631 -
Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
|
||
Active, not recruiting |
NCT02274727 -
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
|
||
Completed |
NCT02225730 -
Imaging Collaterals in Acute Stroke (iCAS)
|
||
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Active, not recruiting |
NCT01581502 -
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
|
N/A | |
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Completed |
NCT00761982 -
Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.
|
Phase 1/Phase 2 | |
Completed |
NCT00535197 -
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
|
Phase 1/Phase 2 | |
Terminated |
NCT00132509 -
FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke
|
Phase 2 | |
Recruiting |
NCT05760326 -
Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
|